Elevance Health Inc.
NYSE:ELVMedical - Healthcare Plans
-$3.45 today
- Market cap
- $85.23B
- Beta
- 0.68
- P/E (TTM)
- 16.3
- EPS (TTM)
- $23.78
- Dividend yield
- 1.77%
Volume 2.04M
Average 1.68M
Returns on capital
Elevance Health Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
12.9%
avg 13.9%
ROIC
6.6%
avg 6.9%
ROA
4.7%
avg 5.2%
Analysis
ROE is currently the strongest return metric at 12.9% versus its period average of 13.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Gail Koziara Boudreaux | President, Chief Executive Officer & Director | USD 4.94M | 65 | — | — |
Peter David Haytaian | Special Advisor | USD 2.06M | 56 | — | — |
Felicia Farr Norwood | Executive VP & Chief Health Benefits Officer | USD 2.03M | 66 | — | — |
Mark Bradley Kaye | Executive Vice President & Chief Financial Officer | USD 2.01M | 46 | — | — |
Charles Morgan Kendrick Jr. | EVP and President of Commercial & Specialty Health Benefits | USD 1.91M | 60 | 11.79K | <0.01% |
Nathan Allen Rich | Vice President of Investor Relations | — | — | — | — |
Ronald William Penczek | Senior Vice President, Controller & Chief Accounting Officer | — | 61 | — | — |
Scott Wayne Anglin | SVP, Treasurer & Chief Investment Officer | — | — | — | — |
Erin Wessling | Executive VP & Chief Legal Officer | — | 48 | — | — |
Julie Goon | Senior Vice President of Public Affairs | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 6, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$2.24M
Sells
19
$6.98M
Net Transaction Value
−$4.74M
Net selling
Most Active
Kaye Mark
13 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 5, 26Nov 5, 2026 | LAVU RATNAKAR Direct | Sell | $572K$572,000.00 |
| Oct 22, 26Oct 22, 2026 | Kaye Mark Direct | Sell | $139.7K$139,715.25 |
| Oct 22, 26Oct 22, 2026 | Kaye Mark Direct | Sell | $724.1K$724,092.00 |
| Oct 22, 26Oct 22, 2026 | Kaye Mark Direct | Sell | $244.8K$244,759.20 |
| Oct 22, 26Oct 22, 2026 | Kaye Mark Direct | Sell | $105.2K$105,172.80 |
| Oct 22, 26Oct 22, 2026 | Kaye Mark Direct | Sell | $509.5K$509,530.00 |
| Oct 22, 26Oct 22, 2026 | Kaye Mark Direct | Sell | $757.6K$757,556.80 |
| Oct 22, 26Oct 22, 2026 | Kaye Mark Direct | Sell | $1M$1,034,059.62 |
| Oct 22, 26Oct 22, 2026 | Kaye Mark Direct | Sell | $212.5K$212,452.80 |
| Oct 22, 26Oct 22, 2026 | Kaye Mark Direct | Sell | $195.3K$195,276.40 |
1–10 of 23
Summary
Insiders reported 4 buys worth $2.24M and 19 sells worth $6.98M over the last 12 months. That adds up to net selling of $4.74M. Kaye Mark was the most active insider with 13 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +1.1% | +13.1% (5yr)1 analysts |
| Revenue | N/A | N/A | +8.3% | +3.6% (5yr)5 analysts |
| Net Income | N/A | N/A | -1.3% | +12.7% (5yr)5 analysts |
| EBIT | N/A | N/A | -1.4% | +12.0% (5yr)5 analysts |
Analysis
Recent growth has been strongest in Revenue at +8.3% over three years. Forward estimates point to EPS at +13.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Elevance Health Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about ELV's management, answered from reported figures.
Who manages ELV?
Elevance Health Inc. (ELV) lists 10 active executives. The top listed executive is Charles Morgan Kendrick Jr., EVP and President of Commercial & Specialty Health Benefits.
Are ELV insiders buying or selling?
Recent insider activity shows net buying of $37.06M.
Continue the stock analysis
Jump to another research area for this company.